<DOC>
	<DOCNO>NCT00321308</DOCNO>
	<brief_summary>To assess efficacy safety PF-3512676 administer combination pemetrexed treatment patient locally advance metastatic NSCLC fail one prior chemotherapy regimen</brief_summary>
	<brief_title>Trial Pemetrexed With Without PF-3512676 Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>PF-3512676 dosing stop 21 June 2007 Pfizer decide stop administration PF-3512676 trial combine PF-3512676 cytotoxic chemotherapy . The decision make subsequent DSMC recommendation close two phase III randomize trial non-small cell lung cancer also combine PF-3512676 cytotoxic chemotherapy , cite lack efficacy concern primary reason safety issue ( sepsis , thrombocytopenia ) also contribute decision . Subjects allow complete standard care treatment protocol follow-up . Data collection complete 31 January 2008 .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Locally advanced metastatic NSCLC Measurable disease ECOG PS 0 1 Known CNS metastasis Preexisting autoimmune antibody mediate disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>advanced carcinoma , non-small cell lung cancer , phase II , pemetrexed , Alimta , PF-3512676 , immunotherapy , immunomodulator</keyword>
</DOC>